Dr. Laszlo Elek Korhaz Es Rendelointezet Oroshaza
- Address
- Kond Utca 59, 5900 Oroshaza, Hungary
Cardiovascular Diseases Research at Dr. Laszlo Elek Korhaz Es Rendelointezet Oroshaza
The site’s clinical research is centered on cardiovascular diseases, with studies focused on people living with established atherosclerotic cardiovascular disease. These trials are designed to evaluate whether new treatments can better reduce the risk of major heart and stroke-related events compared with standard care or placebo.
- Testing a new therapy aimed at lowering the risk of cardiovascular death, heart attack, and ischemic stroke in patients with vascular disease
- Evaluating treatment effectiveness for people with ASCVD who continue to have elevated LDL-C
This work reflects a strong interest in prevention-focused cardiology and improving outcomes for patients already affected by advanced vascular disease.
Heart Failure and Obesity Studies
Another key area at the hospital is research in heart failure, especially heart failure with preserved ejection fraction and mildly reduced ejection fraction in people with obesity. These trials are exploring whether an added treatment can improve symptoms and reduce serious heart failure events or cardiovascular death.
- Assessing a potential new treatment for patients with HFpEF and HFmrEF
- Studying whether therapy can reduce hospitalizations, urgent heart failure visits, and cardiovascular mortality
The research combines cardiology and metabolic health, highlighting efforts to find better options for patients whose heart failure is complicated by excess body weight.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. Laszlo Elek Korhaz Es Rendelointezet Oroshaza
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Inclisiran's Efficacy in Reducing Major Adverse Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial | Novartis Pharma AG | Phase III | Not Recruiting | Nov 2021 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2022-11-24 | 2022-11-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.